Multiple Immune-Related Adverse Event Overlap in Two Patients Treated with Pembrolizumab

Can J Neurol Sci. 2022 Jan;49(1):133-135. doi: 10.1017/cjn.2021.46. Epub 2021 Mar 17.
No abstract available

Keywords: Checkpoint inhibitors; Immune-related adverse events; Inflammatory myopathy; Myasthenia gravis; Myocarditis.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Humanized* / adverse effects
  • Humans
  • Myositis*

Substances

  • Antibodies, Monoclonal, Humanized
  • pembrolizumab